The ARFGEF2 Knockout A-549 Polyclonal Cells product consists of a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line, in which the ARFGEF2 gene has been disrupted through CRISPR/Cas9-mediated gene disruption. This polyclonal population provides a loss-of-function model that enables the study of ARFGEF2-dependent processes without the clonal selection biases inherent in monoclonal lines, making it suitable for bulk functional genomics and drug screening applications where cellular heterogeneity is advantageous. The knockout cells are provided as a ready-to-use, polyclonal format that retains the genetic diversity necessary to recapitulate the heterogeneous responses often observed in tumor biology, while still ablating ARFGEF2 protein expression and downstream functions across the population, as confirmed by standard molecular and biochemical assays.
The host A-549 cell line is a well-established in vitro model of human lung adenocarcinoma, originally derived from the tumor tissue of a 58-year-old Caucasian male. These cells exhibit epithelial morphology and adherent growth, and they are widely recognized as a model for type II alveolar pneumocytes, making them particularly relevant for studies of lung cancer biology, pulmonary drug delivery, and toxicology. The A-549 line carries mutations in key lung cancer?Cassociated pathways, including KRAS and TP53, which contribute to its utility in investigating oncogenic signaling, metastasis, and drug resistance mechanisms. Its robust and reproducible growth characteristics, combined with its genomic and transcriptomic annotation, make it an ideal host for generating ARFGEF2 knockout derivatives for both targeted mechanistic studies and high-throughput approaches.
ARFGEF2 encodes BIG2, a guanine nucleotide exchange factor specifically for the ADP-ribosylation factor (ARF) family of small GTPases, primarily ARF1 and ARF3. BIG2 functions downstream of activated AKT1 and PI3K signaling, and it is recruited to Golgi and endosomal membranes where it catalyzes the GDP-to-GTP exchange on ARF1 and ARF3, thereby triggering their activation. Activated ARF1, in turn, recruits and assembles downstream effectors including the COPI coat complex, GGA adaptor proteins, and clathrin adaptors, which together drive vesicle budding, cargo sorting, and retrograde trafficking between the Golgi and endoplasmic reticulum. Additionally, ARFGEF2 regulates phospholipase D activity, actin cytoskeleton remodeling, and the motor protein KIF5B to coordinate organelle positioning and cell migration. Interacting partners such as ARF5, NCKAP1L, and EXOC2 further implicate ARFGEF2 in exocytosis and cortical actin dynamics, highlighting its central role in coordinating membrane traffic with cell morphology and motility.
In the A-549 lung adenocarcinoma context, ARFGEF2 knockout is predicted to impair ARF GTPase?Cdependent vesicular transport, leading to disrupted Golgi organization, altered secretion of metalloproteinases and growth factors, and defective integrin trafficking, all of which are critical for cancer cell proliferation, invasion, and metastasis. Given the elevated expression of ARFGEF2 observed in lung adenocarcinoma and its association with poor prognosis, this polyclonal knockout model enables researchers to dissect the specific contributions of BIG2 to oncogenic ARF signaling, epithelial-to-mesenchymal transition, and chemoresistance. Furthermore, because ARFGEF2 mutations are linked to periventricular nodular heterotopia, the A-549 knockout system may also serve as a surrogate to explore neurodevelopmental trafficking defects, albeit in a non-neuronal background, providing complementary insights into disease mechanisms.
This polyclonal ARFGEF2 knockout cell product is designed for a broad range of research applications, including the investigation of intracellular trafficking defects in lung cancer, evaluation of drug sensitivity and resistance profiles, high-throughput screening of small molecules targeting ARF pathways, and functional validation of ARFGEF2??s role in cell migration and invasion using Boyden chamber assays. Representative assay strategies include western blotting to verify ARFGEF2 protein ablation, RT-qPCR to quantify residual transcript levels, immunofluorescence staining for Golgi markers such as GM130 to assess organelle integrity, and ARF1 activation pull-downs using GST-GGA3 beads to measure ARF GTPase activity. Proliferation and cell cycle analyses by MTT or flow cytometry, coupled with migration and invasion assays, provide functional readouts, while drug sensitivity panels allow researchers to explore synthetic lethality and resistance mechanisms. For further information, please contact Ascent Research.
